Intech Biopharm Corporation Share Price

Equities

6461

TW0006461007

Pharmaceuticals

End-of-day quote Taipei Exchange 23:00:00 10/07/2024 BST 5-day change 1st Jan Change
29.35 TWD -2.65% Intraday chart for Intech Biopharm Corporation -3.29% -1.84%

Financials

Sales 2022 23.65M 728K 56.11M Sales 2023 25.85M 796K 61.33M Capitalization 4.11B 126M 9.75B
Net income 2022 -328M -10.1M -778M Net income 2023 -338M -10.41M -802M EV / Sales 2022 208 x
Net Debt 2022 1.03B 31.83M 2.45B Net Debt 2023 837M 25.78M 1.99B EV / Sales 2023 191 x
P/E ratio 2022
-11.8 x
P/E ratio 2023
-10.6 x
Employees 82
Yield 2022 *
-
Yield 2023
-
Free-Float 47.28%
More Fundamentals * Assessed data
Dynamic Chart
Intech Biopharm Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Intech Biopharm Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Intech Biopharm Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Intech Biopharm Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Intech Biopharm Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Intech Biopharm Corporation Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Intech Biopharm Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Intech Biopharm Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Intech Biopharm Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Intech Biopharm Corporation Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Intech Biopharm Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021 CI
Intech Biopharm Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2021 CI
Intech Biopharm Corporation Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Intech Biopharm Corporation Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Intech Biopharm Corporation Reports Earnings Results for the Third Quarter Ended September 30, 2020 CI
More news
1 day-2.65%
1 week-3.29%
Current month-0.34%
1 month+8.30%
3 months+2.98%
6 months+2.26%
Current year-1.84%
More quotes
1 week
28.85
Extreme 28.85
31.95
1 month
27.00
Extreme 27
31.95
Current year
25.80
Extreme 25.8
31.95
1 year
24.00
Extreme 24
33.70
3 years
18.00
Extreme 18
46.75
5 years
11.45
Extreme 11.45
46.75
10 years
11.45
Extreme 11.45
126.00
More quotes
Managers TitleAgeSince
Chief Executive Officer - 31/10/11
Director of Finance/CFO - 22/07/13
Chairman - 27/10/10
Members of the board TitleAgeSince
Chairman - 27/10/10
Director/Board Member 66 01/04/14
Chief Executive Officer - 31/10/11
More insiders
Date Price Change Volume
11/07/24 29.35 -2.65% 565,180
10/07/24 30.15 -0.50% 183,104
09/07/24 30.3 -2.88% 497,878
08/07/24 31.2 +1.63% 735,547
05/07/24 30.7 +1.15% 289,076

End-of-day quote Taipei Exchange, July 10, 2024

More quotes
INTECH BIOPHARM LTD. is a Taiwan-based company principally engaged in the research, development, manufacture and sales of inhalants and related products. The Company's main products include respiratory drugs, the Duasma hexafluoroacetone (HFA) metered-dose inhalers (MDIs) and the Synvent HFA MDIs. The Company distributes its products in domestic market and to overseas markets.
More about the company